(MM) News - NBS

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update

NEW YORK, May 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

NeoStem to Present at Multiple May and June Conferences

NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing...

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

NEW YORK, April 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company...

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma PR Newswire LAKE FOREST, Calif., April 29, 2015 LAKE FOREST...

NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency

NEW YORK, April 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company...

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

NEW YORK, April 20, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company...

NeoStem Announces Extension of Study Under Grant From California Institute of Regenerative Medicine (CIRM) to Fund Research o...

NEW YORK, April 9, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing...

NeoStem to Present at Multiple April Conferences

NEW YORK, April 6, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

Current Report Filing (8-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) of the...

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

NEW YORK, March 16, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company...

NeoStem to Present at Two Upcoming Investor Conferences in March

NEW YORK, March 12, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

NeoStem PreSERVE AMI Clinical Trial One-Year Results to be Presented at American College of Cardiology Annual Scientific Sess...

NEW YORK, March 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update

NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a...

Current Report Filing (8-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) of the...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

(MM) (NBS)

Professional-Grade Tools, for Individual Investors.

NBS News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update

NeoStem to Present at Multiple May and June Conferences

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma

NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

NeoStem Announces Extension of Study Under Grant From California Institute of Regenerative Medicine (CIRM) to Fund Research o...

NeoStem to Present at Multiple April Conferences

Current Report Filing (8-k)

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

NeoStem to Present at Two Upcoming Investor Conferences in March

NeoStem PreSERVE AMI Clinical Trial One-Year Results to be Presented at American College of Cardiology Annual Scientific Sess...

NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update

Current Report Filing (8-k)

NBS Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

(MM) (NBS) News

(MM) (NBS)

Professional-Grade Tools, for Individual Investors.

NBS News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update

NeoStem to Present at Multiple May and June Conferences

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma

NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

NeoStem Announces Extension of Study Under Grant From California Institute of Regenerative Medicine (CIRM) to Fund Research o...

NeoStem to Present at Multiple April Conferences

Current Report Filing (8-k)

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

NeoStem to Present at Two Upcoming Investor Conferences in March

NeoStem PreSERVE AMI Clinical Trial One-Year Results to be Presented at American College of Cardiology Annual Scientific Sess...

NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update

Current Report Filing (8-k)

NBS Discussion

Your Recent History